GLUE — MONTE ROSA THERAPEUTICS INC

Ownership history in Rangeley Capital, LLC  ·  2 quarters on record

This page tracks every 13F SEC filing in which Rangeley Capital, LLC reported a position in MONTE ROSA THERAPEUTICS INC (GLUE). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.88% (2025 Q4)
Avg. % of fund
0.8%
First filed
2025 Q3
Last filed
2025 Q4
Quarters held
2
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 REDUCED 67,500 -45,500 -40.3% 0.88% $1.1M $15.68
2025 Q3 INITIATED 113,000 — — 0.72% $837K $7.41
% of Fund (quarterly)    GLUE price (monthly, adj. close)

Other funds also holding GLUE

As of 2025 Q4 — sorted by position size

Versant Venture Management, LLC 3Y 7Y 45.49% NEA Management Company, LLC 3Y 7Y 6.15% Aisling Capital Management LP 3Y 7Y 4.82% TCG Crossover Management, LLC 3Y 2.4% SILVERARC CAPITAL MANAGEMENT, LLC 3Y 2.24% MPM BioImpact LLC 3Y 2.11% BVF INC/IL 3Y 7Y 2.02% SUVRETTA CAPITAL MANAGEMENT, LLC 3Y 7Y 1.08% Parkwood LLC 3Y 7Y 0.86% BRAIDWELL LP 3Y 0.48%
← Back to Rangeley Capital, LLC Holdings